Sort by
Items per page

Send to

Choose Destination

Search results

Items: 17


Preclinical Evaluation of the Pan-FGFR Inhibitor LY2874455 in FRS2-Amplified Liposarcoma.

Hanes R, Munthe E, Grad I, Han J, Karlsen I, McCormack E, Meza-Zepeda LA, Stratford EW, Myklebost O.

Cells. 2019 Feb 21;8(2). pii: E189. doi: 10.3390/cells8020189.


Noninvasive Detection of ctDNA Reveals Intratumor Heterogeneity and Is Associated with Tumor Burden in Gastrointestinal Stromal Tumor.

Namløs HM, Boye K, Mishkin SJ, Barøy T, Lorenz S, Bjerkehagen B, Stratford EW, Munthe E, Kudlow BA, Myklebost O, Meza-Zepeda LA.

Mol Cancer Ther. 2018 Nov;17(11):2473-2480. doi: 10.1158/1535-7163.MCT-18-0174. Epub 2018 Aug 10.


Preclinical Evaluation of Vemurafenib as Therapy for BRAFV600E Mutated Sarcomas.

Gouravan S, Meza-Zepeda LA, Myklebost O, Stratford EW, Munthe E.

Int J Mol Sci. 2018 Mar 23;19(4). pii: E969. doi: 10.3390/ijms19040969.


Pml nuclear body disruption cooperates in APL pathogenesis and impairs DNA damage repair pathways in mice.

Voisset E, Moravcsik E, Stratford EW, Jaye A, Palgrave CJ, Hills RK, Salomoni P, Kogan SC, Solomon E, Grimwade D.

Blood. 2018 Feb 8;131(6):636-648. doi: 10.1182/blood-2017-07-794784. Epub 2017 Nov 30.


Analysis of the miR-34 family functions in breast cancer reveals annotation error of miR-34b.

Engkvist ME, Stratford EW, Lorenz S, Meza-Zepeda LA, Myklebost O, Munthe E.

Sci Rep. 2017 Aug 28;7(1):9655. doi: 10.1038/s41598-017-10189-1.


A PML/Slit Axis Controls Physiological Cell Migration and Cancer Invasion in the CNS.

Amodeo V, A D, Betts J, Bartesaghi S, Zhang Y, Richard-Londt A, Ellis M, Roshani R, Vouri M, Galavotti S, Oberndorfer S, Leite AP, Mackay A, Lampada A, Stratford EW, Li N, Dinsdale D, Grimwade D, Jones C, Nicotera P, Michod D, Brandner S, Salomoni P.

Cell Rep. 2017 Jul 11;20(2):411-426. doi: 10.1016/j.celrep.2017.06.047.


Monogenic and polygenic determinants of sarcoma risk: an international genetic study.

Ballinger ML, Goode DL, Ray-Coquard I, James PA, Mitchell G, Niedermayr E, Puri A, Schiffman JD, Dite GS, Cipponi A, Maki RG, Brohl AS, Myklebost O, Stratford EW, Lorenz S, Ahn SM, Ahn JH, Kim JE, Shanley S, Beshay V, Randall RL, Judson I, Seddon B, Campbell IG, Young MA, Sarin R, Blay JY, O'Donoghue SI, Thomas DM; International Sarcoma Kindred Study.

Lancet Oncol. 2016 Sep;17(9):1261-71. doi: 10.1016/S1470-2045(16)30147-4. Epub 2016 Aug 4.


Preclinical evaluation of potential therapeutic targets in dedifferentiated liposarcoma.

Hanes R, Grad I, Lorenz S, Stratford EW, Munthe E, Reddy CC, Meza-Zepeda LA, Myklebost O.

Oncotarget. 2016 Aug 23;7(34):54583-54595. doi: 10.18632/oncotarget.10518.


HSP90 inhibition blocks ERBB3 and RET phosphorylation in myxoid/round cell liposarcoma and causes massive cell death in vitro and in vivo.

Safavi S, Järnum S, Vannas C, Udhane S, Jonasson E, Tomic TT, Grundevik P, Fagman H, Hansson M, Kalender Z, Jauhiainen A, Dolatabadi S, Stratford EW, Myklebost O, Eriksson M, Stenman G, Schneider-Stock R, Ståhlberg A, Åman P.

Oncotarget. 2016 Jan 5;7(1):433-45. doi: 10.18632/oncotarget.6336.


Metabolic reprogramming of metastatic breast cancer and melanoma by let-7a microRNA.

Serguienko A, Grad I, Wennerstrøm AB, Meza-Zepeda LA, Thiede B, Stratford EW, Myklebost O, Munthe E.

Oncotarget. 2015 Feb 10;6(4):2451-65.


Functional genomics analysis reveals a MYC signature associated with a poor clinical prognosis in liposarcomas.

Tran D, Verma K, Ward K, Diaz D, Kataria E, Torabi A, Almeida A, Malfoy B, Stratford EW, Mitchell DC, Bryan BA.

Am J Pathol. 2015 Mar;185(3):717-28. doi: 10.1016/j.ajpath.2014.11.024. Epub 2015 Jan 23.


The tankyrase-specific inhibitor JW74 affects cell cycle progression and induces apoptosis and differentiation in osteosarcoma cell lines.

Stratford EW, Daffinrud J, Munthe E, Castro R, Waaler J, Krauss S, Myklebost O.

Cancer Med. 2014 Feb;3(1):36-46. doi: 10.1002/cam4.170. Epub 2013 Dec 17.


Epigenetic regulation and functional characterization of microRNA-142 in mesenchymal cells.

Skårn M, Barøy T, Stratford EW, Myklebost O.

PLoS One. 2013 Nov 13;8(11):e79231. doi: 10.1371/journal.pone.0079231. eCollection 2013.


Functional characterisation of osteosarcoma cell lines and identification of mRNAs and miRNAs associated with aggressive cancer phenotypes.

Lauvrak SU, Munthe E, Kresse SH, Stratford EW, Namløs HM, Meza-Zepeda LA, Myklebost O.

Br J Cancer. 2013 Oct 15;109(8):2228-36. doi: 10.1038/bjc.2013.549. Epub 2013 Sep 24.


Photochemical internalization of CD133-targeting immunotoxins efficiently depletes sarcoma cells with stem-like properties and reduces tumorigenicity.

Stratford EW, Bostad M, Castro R, Skarpen E, Berg K, Høgset A, Myklebost O, Selbo PK.

Biochim Biophys Acta. 2013 Aug;1830(8):4235-43. doi: 10.1016/j.bbagen.2013.04.033. Epub 2013 May 2.


Characterization of liposarcoma cell lines for preclinical and biological studies.

Stratford EW, Castro R, Daffinrud J, Skårn M, Lauvrak S, Munthe E, Myklebost O.

Sarcoma. 2012;2012:148614. doi: 10.1155/2012/148614. Epub 2012 Jul 14.


Liposarcoma Cells with Aldefluor and CD133 Activity have a Cancer Stem Cell Potential.

Stratford EW, Castro R, Wennerstrom A, Holm R, Munthe E, Lauvrak S, Bjerkehagen B, Myklebost O.

Clin Sarcoma Res. 2011 Aug 1;1(1):8. doi: 10.1186/2045-3329-1-8. Epub 2011 Aug 1.

Supplemental Content

Loading ...
Support Center